DiscoveRx – cell-based assays

DiscoveRx is an innovative biotech company developing reagents, complete cell-based assay kits, profiling and screening services for life science and drug discovery markets.

DiscoveRx – cell-based assays


DiscoveRx pioneered the use of β-galactosidase enzyme fragment complementation (EFC) for discovery research, and EFC-based HitHunter cAMP assays are the market leader in GPCR screening applications. PathHunter and InCELL Hunter technology platforms are innovative adaptations of EFC technology allowing live cell-based assays for pathway profiling and compound screening. DiscoveRx also holds extensive intellectual property for its second core technology, KINOMEscan, an in vitro binding assay platform. This KINOMEscan technology was also adapted to propose a bromodomain reader proteins named BROMOscan. DiscoveRx’s biochemical and cell-based assays enable researchers to improve productivity and effectiveness of their screening, thus accelerating the discovery and development of new drugs. Furthermore, the BioMAP platform of human primary cell systems for phenotypic profiling offers a powerful tool to deliver physiologically relevant solutions for all stages of discovery (from lead discovery to preclinical). Thus, DiscoveRx is able to offer assay solutions for every major class of drug target, including kinases, GPCRs, bromodomains, proteases, methyltranseferases, nuclear hormone receptors, transcription factors, cytokines and secreted proteins. DiscoveRx also develops a robust, reliable, and sensitive fluorometric technology platform to analyze various intracellular analytes (calcium, IP3, ADP, etc…). These fluorometric assays are homogenous, HTS-adaptable and cost-effective assays designed for precise, highly sensitive detection of specific analytes.

DiscoveRx was founded in January 2000 as a spin-off from Microgenics. DiscoveRx is a privately held company headquartered in Fremont (USA) with additional offices in San Diego (USA) and Birmingham (UK). Board of Directors is composed by Pyare Khanna (CEO), Esfandiar Lohrasbpour, Scott Halsted, Melissa Daniels, Morgan Stanley and Richard Bastiani.

More about DiscoveRx:

DiscoveRx – cell-based assay kit – β-galactosidase – enzyme fragment complementation – EFC – GPCR screening – PathHunter – InCELL Hunter – KINOMEscan – intracellular analyte – calcium – IP3 – ADP – fluorometric assay

DiscoveRx – cell-based assay kits – profiling – screening – β-galactosidase enzyme fragment complementation – HitHunter – cAMP assay – KINOMEscan – KINOME scan – BROMOscan – BROMO scan – BioMAP – kinase – GPCR – bromodomain – protease – methyltranseferase – nuclear hormone receptor – transcription factor – cytokine – secreted protein – Microgenics – Pyare Khanna – Esfandiar Lohrasbpour -Scott Halsted – Melissa Daniels – Morgan Stanley – Richard Bastiani